+34 679 490 537info@nanbiosis.com



04 Feb

NANBIOSIS Against Cancer

The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths. Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%. The only way to understand cancer and,[...]

14 Nov

Drive Pannel Diabetes - Nanbiosis
Diabetes mellitus and pancreatic islet transplant: DRIVE

Today in the World Diabetes Day it is a good moment to remember The Patient Panel of the European project DRIVE- Diabetes Reversing Implants, held in Vitoria (Alava) on June 2 where researches and doctors met with patients and families. The Panel was organized by the NanoBioCel group of CIBER BBN and NANBIOSIS Unit 10 Drug Formulation, with the purpose of letting know the DRIVE project to patients and concect patients with the project scientists and experts in pancreas and stem cell transplantation. Thus, one of the most important health objectives of the European Union was met: to promote direct[...]

19 Jul

Mechanical Characterization of soft biological tissues - Nanbiosis
Mechanical Characterization of soft biological tissues

The experimental study of the mechanical properties of biological tissues is of vital importance. Thorough research into themechanical response of biomaterials is the basis for the creation ofmodels which can accurately reproduce the mechanical behavior ofsuch materials. Adequate mechanical characterization of tissue materials is of paramount interest to the clinical simulations, diagnostic and tissue engineering fields – where the tissue structure, in contrast to classical mechanics application fields, is just simply a biological tissue. In order to obtain their material properties, classical engineering testing techniques have been applied to biologicalmaterials. To reproduce the mechanical behavior of these kinds ofmaterial, many[...]

16 Jan

U12-Nanostructured liquid characterization unit
Characterization of nanomedicines

The quick development of nanotechnology and its application in medicine have generated new alternatives for the diagnosis and treatment of diseases thanks to the novel methods of preparation, modification and characterization of nanomaterials. The knowledge about the behavior of matter at the atomic and molecular level has allowed the creation of tools and processes to observe manipulate and control biological structures on a scale between 100 and 10,000 times smaller than a mammalian cell. Nanomedicine is defined as the application of nanotechnology in view of making a medical diagnosis or treating or preventing diseases. It exploits the improved and often[...]

News about Nanbiosis

23 Aug

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

Three units of NANBIOSIS have collaborated in obtaining the research results published in the article “Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies” published by Advanced Science Protein production and DLS have been partially performed by the Unit 1 of ICTS NANBIOSIS Protein Production Platform (PPP) and the Unit 6 NANBIOBIS Biomaterial Processing and Nanostructuring Unit. Biodistribution and immunohistochemistry assays were performed at NANBIOSIS U20 In Vivo Experimental Platform/FVPR Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44‐targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types[...]

22 Aug


Next October 15-18, the researchers of NANBIOSIS U12, Nanostructured liquid characterization unit, are giving a course on Nano Technologies and Microencapsulation organized by CSIC General Foundation and CUIMPB – Center Ernest Lluch of the Menéndez Pelayo International University (UIMP) in Barcelona. The nano- and microencapsulation consists in the protection of active substances inside nano- and microcarriers, particularly labile molecules, improving their stability, with the aim of transporting them and achieving their controlled release. This topic is the subject of great interest in numerous fields and industrial applications. It is known that the performance efficiency of an active substance greatly increases[...]

21 Aug

AKT2 as a promising target for future anti-cancer therapies

The researchers of NANBIOSIS U20, led by Ibane Abásolo and Simó Schwartz have published a new article on the scientific magazine Cancers, with the title Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells All the in vivo studies were performed by NANBIOSIS U20 In Vivo Experimental Platform. Therapeutic resistance seen in aggressive forms of breast cancer remains challenging for current treatments. More than half of the patients suffer from a disease relapse, most of them with distant metastases. Cancer maintenance, resistance to therapy, and metastatic disease seem to be sustained by the presence of cancer stem[...]

20 Aug

New publication by scientists of NANBIOSIS Unit 6 aims to motivate scientific community to start a new research line for organic and bio-organic electronics focused on the device fabrication

Researchers of Nanomol Group, coordinator of NANBIOSIS U6 of CIBER-BBN and ICMAB-CSIC, led by Inma Ratera and Jaume Veciana have publish a new article titled “Reversible switching of the Au(111) work function by near infrared irradiation with a bistable SAM based on a radical donor–acceptor dyad“, at Journal of Materials Chemistry C. Article: https://pubs.rsc.org/en/content/articlelanding/2019/TC/C9TC00906J#!divAbstract[...]

17 Aug

The Autonomous University of Barcelona, in the elite of the 300 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide, based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The Autonomous University of Barcelona houses two of NANBIOSIS Units: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Paolo Saccardo, offer an “tailored” service for the design, production and purification[...]

16 Aug

The University of Zaragoza, in the elite of the 500 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, once again places the University of Zaragoza among the elite of the 500 best universities in the world. This indicator organizes up to 20,000 university centers worldwide. Among the keys that have been able to positively influence the results of the research, according to the Vice Chancellor for Prospect, Sustainability and Infrastructure of the University of Zaragoza, Francisco Serón, are the increase in public campus funding for four years as well as the quality of their Scientists. The University of Zaragoza houses[...]

02 Aug

Scientific breakthrough against the problems of advanced age in fertility.

Researchers of CCMIJU. led by Javier G. Casado, Scientific Director of NANBIOSIS U14 Cell Therapy, are coauthors of the article “Extracellular vesicles derived from endometrial human mesenchymal stem cells enhance embryo yield and quality in an aged murine model” published by. Biology of Reproduction, The study of the beneficial effect of endometrial stem cell exosomes on embryonic quality has been developed in NANBIOSIS U14 and in collaboration with U22 and U23 Advanced age is a risk factor undermining women’s fertility. Hence, the optimization of assisted reproduction techniques is an interdisciplinary challenge that requires the improvement of in vitro culture systems. Here, w[...]

30 Jul

Nanomol group initiates contact with the AEMPS to bring a new treatment against venous leg ulcers to the clinic

Researchers of the Nanomol group, ICMAB-CSIC and CIBER-BBN members of the ICTS “NANBIOSIS”, specifically of the Biomaterial Processing and Nanostructuring unit (U6), together with the company Nanomol Technologies S.L. have begun a consultation process with the Spanish Association of Medicines and Health Products (AEMPS) to try and enter a new treatment in a clinical studies stage, to fight against venous ulcers in lower extremities. The study is carried out within the framework of the RIS3CAT NANONAFRES project. Approximately, 80% of ulcers in lower extremities have associated pathologies of venous insufficiency and these wounds are usually recurrent. An open ulcer can[...]

29 Jul

Making the most from Signals in Biomedical applications.

Last week took place on Berlin the EMB Conference 2019, (the 41st  International Engineering in Medicine and Biology Conference) with the overarching theme “Biomedical engineering ranging from wellness to intensive care” counting with plenary keynotes from leading academic and industrial scientists, who presented aspects of innovation and translational engineering in biomedicine. Pablo Laguna, Scientific Director of NANBIOSIS Unit 27, from CIBER-BBN and I3A-UZ, was invited to give a talk on the topic “Phisiologically Driven Biomedical Signal Processing: making the most of Signals” Pablo Laguna has co-authored more than 150 research papers on this topic, over 300 international conference papers, and has advise 15 Ph.D[...]

18 Jul


Last week, representatives of NANBIOSIS and OmicsTech met at the IQAC-CSIC facilities in Barcelona to exchange common research lines, points of view of their complementarity and collaboration possibilities of the facilities, both recognized as Unique Scientific Technical Infrastructure (ICTS) by the Spanish Government. The Infrastructure for Omics Technologies OmicsTech ICTS is a distributed infrastructure that offers researchers the possibility of using globally competitive singular facilities exclusively dedicated to work with omics technologies, with a spectrum of biomolecular analysis tools for holistic capture of biological processes, to support research, technological development, and innovation activities. Advances in genomics, proteomics and metabolomics technologies have opened[...]

08 Jul

Agreement signed with Spanish Goverment for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, a projects related to the ICTS NANBIOSIS has been selected by the Ministry of Science, Innovation and Universities for co-financing with FEDER funds of the European Regional Development Funds program. An agreement has been signed between Ministry of Science, Innovation and University of Extremadura, institution that houses NANBIOSIS unit 16 for the co-financing of the Project FICTS1420-14-09: “Compra e instalación y puesta a punto de equipamiento de caracterización para complementar la Unidad 16 de NANBIOSIS – Surface Characterization and Calorimetry Unit –NANBIOSISU16”.[...]

27 Jun

Judit Tomsen: Best oral presentation at ESC 2019

Last June 18-22 at the 2019, ESC meeting, the European Students Colloid Conference, that took place in Varna, Bulgaria, Judit Tomsen,  PhD fellow at the Nanomol group from CIBER-BBN and ICMAB-CSIC, was awarded with the best oral presentation. Judit Tomsen, who carries out her work under supervision of Nora Ventosa,  Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit, presented her oral communication entitled “Design of peptide targeted nanovesicles for the α-galactosidase A enzyme delivery“. Her talk explained some of the smart4fabry european project results, a project coordinated by CIBER-BBN and Nora Ventosa in which participates NANBIOSIS Unit 6. The European Colloids and Interfaces Society (ECIS) organizes biannually ESC meetings of advanced students at PhD and MSc[...]

25 Jun

Do you want to join the nanotechnology revolution?

From the NFP research group of CIBER-BBN and INA, led by Jesus Santamaria, that coordinates NANBIOSIS U9 Synthesis of Nanoparticles Unit, and through the SAMCA Nanotechnology Chair, the call for grants has been launched: Nanotechnological Bonds For more information: http://capsulasdenanotecnologia.es/bonos-nanotec/[...]

24 Jun

NANBIOSIS U20 at the Nanomed Europe Conference, NME19.

Last week took place in Braga, Portugal, the Nanomed Europe Conference, NME19, a new and unique conference  born from the merge of the 14th annual event of the ETPN & the European scientific conference ENM (after London 2017 & Grenoble 2015), bringing together scientists, technology providers, entrepreneurs, industry and clinicians, all of them developing great medical applications of Nanotechnologies and emerging MedTech. The event is been co-organized this year by the ETPN and INL. Simó Schwartz, Scientific Director of NANBIOSIS U20, was one of the selected speakers and gave a lecture about “Preclinical development of magnetic nanoparticles for the treatment of pancreatic cancer” Two posters mentioning t[...]

21 Jun

Agreement signed with Spanish Goverment for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, a projects related to the ICTS NANBIOSIS has been selected by the Ministry of Science, Innovation and Universities for co-financing with FEDER funds of the European Regional Development Funds program. An agreement has been signed between Ministry of Science, Innovation and UPV/EHU (University of the Basque Country ), institution that houses NANBIOSIS unit 10 for the co-financing of the Project FICTS-1420-17: “Purchase and installation and set-up of characterization equipment to complement Unit 10 of drug formulation”.[...]

12 Jun

Laparoscopic surgery in the uterus retrieval procedure during uterine transplantation

Researchers of NANBIOSIS units at JUMISC have recently published the results of an study that highlights the promising application of laparoscopy for graft procurement surgery in uterine transplantation from living donors for absolute uterine infertility treatment. Laparoscopy seems to be a safe, time saving, useful and technically feasible surgical procedure for uterus extraction, with the additional benefits of minimally invasive surgery. It was also demonstrated that after a successful uterine transplant, pregnancy can be achieved by combining laparoscopy for uterine retrieval and microsurgery for vascular anastomosis. With the increasing success rate of human uterus transplantation trials from living donors, it[...]

04 Jun

New Antimicrobial surfaces with self-cleaning properties and NANBIOSIS Unit 17

In the last decades, increased resistance to conventional antibiotics has led to important research in the development of alternative strategies for preventing pathogen dissemination. Antimicrobial surfaces containing a biocidal agent inhibit or reduce microorganisms growth capacity on the surface of materials. In addition to this microbial proliferation inhibition, antimicrobial coatings may also confer additional properties. Researchers from the University of Alcalá and the CSIC Institute of Catalysis and Petrochemistry, have carried out a research about the self-cleaning properties of antimicrobial surfaces functionalized by photocatalytic ZnO electrosprayed coatings. The authors prepared electrosprayed photoactive coatings of sol-gel ZnO nanoparticles tested as dua[...]

31 May

NANBIOSIS U27 propose a mew method for assessing nonlinear cardiorespiratory interactions

Researches of NANBIOSIS Unit 27 High Performance Computing, S. Kontaxis, J. Lázaro, E. Gil, P. Laguna, and R. Bailón are the authors of an article recently published by IEEE Transactions Biomedical Engineering Alternations of cardiorespiratory interactions are related to Autonomic Nervous System (ANS) dysfunction and physiological regulation of the Heart Rate Variability (HRV) in cardiovascular diseases. In this study, a method for assessing nonlinear cardiorespiratory interactions is proposed, quantifying the Quadratic Phase Coupling (QPC) between respiration and HRV. Quadratic cardiorespiratory couplings are studied during a tilt table test protocol on young healthy subjects. Results show a significant reduction of QPC[...]

30 May

NANBIOSIS unit 13 participation at the VIII Conference of Young Researchers of I3A-UZ

Next Thurstday, June 6th, the “Aragón Engineering Research Institute” (I3A) of University of Zaragoza will hold the “VIII Conference of Young Researchers” at the Conference Room Building. R & D (block 1, 1st floor) Researchers of NANBIOSIS unit U13 Tissue & Scaffold Characterization Unit will present their works In the oral presentations section, Mohamed H. Doweidar will talk about Cell behavior under hypoxic conditions. Computational 3D model. In the posters section in the area of ​​BIOMEDICAL ENGINEERING the researchers of unit 13 will present the following results. Design of a microfluidics system for the simulation of the formation of atheromatous[...]

29 May

Mechanism of interaction of a material (pharmaceutical, food, construction, chemical, etc.) with moisture or with any organic vapor.

Next June 11, 2019, from 09:30h to 17:00h, will take place in Eureka Building – Parc de Recerca, UAB (Barcelona), a Scientific-Theoretical / Practical Workshop on: DYNAMIC SORPTION OF VAPORS (DVS – DYNAMIC VAPOR SORPTION) AND CHARACTERIZATION OF MATERIALS (iGC / SEA – INVERSE GAS CHROMATOGRAPHY / SURFACE ENERGY ANALYZER) FOR THE ANALYSIS OF THE SORTION OF WATER AND ORGANIC VAPORS, AND CHARACTERIZATION OF MATERIALS AND SURFACES. The event is organized by IESMAT, S.A. in collaboration with Nanomol Technologies SL, the Institute of Materials Science of Barcelona (ICMAB-CSIC), Surface Measurement Systems (SMS) and the Center for Biomedical Research in Network[...]

24 May

Quantification of Ventricular Repolarization Variation for Sudden Cardiac Death Risk Stratification in Atrial Fibrillation

ATRIAL fibrillation (AF) is the most prevalent sustained arrhythmia and it has become one of the most important public health issues in developed countries. It is expected to double its incidence by 2030 [1], [2], representing the major cause of hospitalizations in elderlies (≥65 years), together with chronic heart failure Alba Martín-Yebra and Juan Pablo Martínez, scientists of NANBIOSIS U27 High Performance Computing, have led the research that proves that it is possible to stratity AF patients at risk of sudden cardiac death (SCD) what could help cardologists to implement better solutions. The computation was performed by the ICTS NANBIOSIS,[...]

23 May

Preclinical molecular imaging and its application to biomedical research

During the days 22-24 of May is taking place in Madrid the 3rd Workshop of introduction to the preclinical molecular image and its application to biomedical research,. The wokshop has been organized by the Health Research Institute of the Gregorio Marañón Hospital, the Complutense University of Madrid and the Madrilenian Network of nanomedicine in molecular imaging (RENIM-CM). The program counts with theoretical sessions of introduction to the physical foundations of each one of the modalities of image and its applications to preclinical biomedical research, as well as practical demonstrations of said image techniques. Ibane Abásolo, Scientific Coordinator of Unit 20[...]

22 May

An Eskimo in the desert

An Eskimo in the desert is the title of the talk that Ignacio Ochoa Researcher of NANBIOSIS U13 Tissue & Scaffold Characterization Unit is giving today at the Pint of Science Festival in Zaragoza at 19:00. One of the greatest advances in biomedicine was to achieve, at the end of the 19th century, maintain human cells outside the body in order to study them. This breakthrough has allowed us, for example, to discover new drugs and evaluate the toxicity of many compounds. Unfortunately, this progress has hardly evolved over these 125 years. However, the arrival of microfluidic technology has allowed[...]

21 May


Francisco Miguel Sánchez Margallo, Scientific Director of the Minimally Invasive Surgery Center ‘Jesús Usón’ and Deputy Director of NANBIOSIS, leads, together with Thomas Malone, of the Massachusetts Institute of Technology (MIT), in the United States, the project selected by the MIT program -Spain ‘La Caixa’ Foundation Seed Fund “Developint a sensor framework for minimally invasive surgery”. The project seeks to develop a system of sensors to analyze health parameters of the surgeon, such as his physiological and ergonomic state, as well as the interaction between this and the patient during surgery. It is a disruptive research project on sensors to[...]

20 May

Multiparametric MR approaches for non-invasive glioblastoma therapy response follow-up (MAGRes)

Ana Paula Candiota, Scientific coordinator of U25 of NANBIOSIS, is the IP of the granted project Multiparametric MR approaches for non-invasive Glioblastoma therapy response follow-up (MAGRes), selected for funding in the ATTRACT call https://attract-eu.com/the-project/ The kick-off meeting for is taking place at CERN, Switzerland, days 20-21th May with talks of all selected projects. Unit 25 will have a relevant role in the development of MAGRes. MRI/MRSI from preclinical brain tumors will be acquired at NANBIOSIS U25, NMR: Biomedical Applications I[...]

17 May

Job Vacancy for position of Project Manager at CIBER

Scientist aiming at developing a career in project management is required for a European Project in the field of biomedical research; working with NANBIOSIS ICTS (Scientific infraestructure of CIBER-BBN). The position requires good command of English and strong skills in coordinating researchers. Applications must be filed at CIBER’s web portal untill May 22.[...]

16 May

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies. During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY. Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis.[...]

14 May

Diabetes mellitus type 1: new system for treatment

The research carried out by the NanoBiocells group, coordinator of NANBIOSIS U10 Drug Formulation unit, from CIBER-BBN and UPV-EHU, with BIOMICS group of UPV-EHU was yesterday highlighted in Catalunya Vanguardista and Noticiasdelaciencia.com. The research reduces the volume of implantation of microcapsules containing insulin-producing pancreatic cells by almost 80% thanks to an innovative system of Magnetic separation of microcapsules. In this way, the medical complications derived from the implantation of large volumes of microcapsules decrease and the treatment of type 1 diabetes mellitus improves. More information: https://www.catalunyavanguardista.com/nuevo-sistema-para-el-tratamiento-de-diabetes-mellitus-tipo-1/[...]

13 May

Biomedical devices with natural fluorescence for monitoring in the body

Researchers from the NanoBioCel and the ICTS NANBIOSIS through the Drug Formulation Unit 10 of CIBER-BBN and the University of the Basque Country (UPV/EHU), together with the University of Michigan (USA), have developed a biomedical cellular immunoisolation device (microcapsules) with intrinsic capacity to be traced once implanted in the organism. The novel design incorporates a natural substance called genipine, which emits intense and stable fluorescence in the far red range. Drug Formulation Unit 10 of Nanbiosis has worked in the design and development of fluorescent particles for use in experimental animals. Non-invasive monitoring of implanted hydrogel-based biosystems generally requires indirect[...]

08 May

CIBER offers two Degree positions for NANBIOSIS (Project Mananger and Researcher) in the frame of a H2020 project.

CIBER-BBN offer two possitions for a project manager (PRF-1768 https://www.ciberisciii.es/empleo/detalle-oferta?id=1768 )  and a researcher (PRF-1766 https://www.ciberisciii.es/empleo/detalle-oferta?id=1766) CIBER is looking for candidates for the selection of a project manager (https://www.ciberisciii.es/empleo/detalle-oferta?id=1768) and a researcher (ttps://www.ciberisciii.es/empleo/detalle-oferta?id=1766) to work in the framework of a European H2020 project. SAFE-N-MEDTECH is an Open-Innovation Test Bed for Safety Testing of Medical Technologies for Health – H2020 NMBP (Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing) medtech project, that has just been launched. The project SAFE-N-MEDTECH will build an innovative open access platform providing reference laboratories and companies with the capabilities, know-how, networks and services needed for developing, testing, evaluating, optimizing and[...]

07 May

The first Nanocomposite that slows the spread of colon cancer

The creation of a nanodrug capable of blocking the spread of the disease, which is known as metastasis, has been highlighted by Guia Medica, as a heavy blow struck against to colon cancer, the malignant tumor with the highest incidence in our country, a process that affects 40% of the million cases of this type of cancer that are diagnosed every year in the world, and that represents the main cause of death. The research, jointly carried out by scientists from the IIB Sant Pau, Sant Pau Hospital, the UAB, CSIC and CIBER-BBN, led by Esther Vázquez and Antonio Villaverde, Strategy[...]

06 May

Polymers and medical applications: Success Cases of Preclinical Research

Next May 10, a conference on “Polymers and medical applications” will be held in Vizcaya, with the participation of NANBIOSIS Deputy Director, and JUMISC Scientific Director Dr. Francisco Miguel Sánchez Margallo, as guest speaker, who will give the lecture “Preclinical Research: Success Cases“ The event will count also with the expertise of Dr. Miguel Angel Martínez, Scientific Director of NANBIOSIS U13 Tissue & Scaffold Characterization Unit, talking about “Modeling and simulation in biomedical applications” Other topics that will be discussed at the Conference will be Hydrogels, Nanogels and Nanoparticles for Controlled Release of Bioactive Substances, The Microfluidics as a Tool for the Development of “Organ-on-a-chip and t[...]

30 Apr

3D cross-correlation dynamic light scattering (DLS) spectrometer of NANBIOSIS U12 has been upgraded

The 3D cross-correlation dynamic light scattering (DLS) spectrometer of NANBIOSIS U12 Nanostructured liquid characterization unit has been upgraded with a new goniometer and last generation laser detectors and beam splitters that allow to extend the scattering angle detection range to 10-150 degrees, and enables measurements in shorter scattering lengths for highly turbid and/or concentrated samples. Non-ergodic samples (e.g. gels) can also be measured with the new configuration The upgrade has been funded by CSIC through the grant “Special fund for the support of Scientific and Technical Services 2018” (02045)[...]

14 Apr

Why peripheral blood lymphocyte alterations can be good biomarkers to predict myocardial infarction severity

Researchers of CCMIJU led by Verónica Crisóstomo, Scientific Director of NANBIOSIS U24 Medical imaging, and Javier García Casado Scientific Director of NANBIOSIS U14 Cell Therapy unit have carried out a study study aimed to identify which are the very early immune-related biomarkers that may be used as predictors of myocardial infarction severity. Experimental studies have been conducted by NANBIOSIS Units 14, 21, 22 and 24 of the CCMIJU, clinical test lab, animal housing, experimental operating room and medical imaging tecniciansare are recognized in the acknowledgement and funding sections of the article. Article of reference: Esther López, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Rebeca Blázquez, Federica Marinaro, Ana Abad,[...]

12 Apr

New tensiometer for NANBIOSIS Unit 12

The new Biolin Sigma 701 has replaced the previos KSV Sigma 700. in the equipment of NANBIOSIS U12 Nanostructured liquid characterization unit With this new tensiometer automated and high precision measurement of surface and interfacial tensions, contact angles and critical micelle concentrations will be obtained. The purchase of the new tensiometer has been co-funded by the CSIC through a grant received from the Scientific and Technical Services support (MEC1372).[...]

09 Apr

Infertility: Exosomal microRNAs in seminal plasma as sensitive and specific biomarkers of the presence of testicular spermatozoa for azoospermia

NANBIOSIS ICTS coordination equipment has recently received from researchers of Human Molecular Genetics Group of Bellvitge Biomedical Research Institute (IDIBELL) a publication mentioning NANBIOSIS in the Acknowledgements for its participation in the results of its investigations. The article has been publish by the journal Human Reproduction of OXFORD UNIV PRESS  with Quartile 1/ Decile 1. The study carried out by  Maria Barcelo, Ana Mata, Lluís Bassas, and Sara Larriba demonstrates the potential of several miRNAs contained in small extracellular vesicles (sEVs) of seminal fluid as sensitive and specific biomarkers for selecting those azoospermic individuals with real chances of obtaining spermatozoa[...]

06 Apr

NANOMOL group, coordinator of NANBIOSIS Unit 6 collaborates with the VHIR in the developement of a new nanomedicine for the treatment of a childhood cancer

Within the MOTHER project (Molecule-based materials and supramolecular organizations for therapy, diagnosis and tissue engineering), the NANOMOL group from ICMAB collaborates with the Vall d’Hebron Institute of Research (VHIR), on the developement of a new nanomedicine for the treatment of high risk neuroblastoma, one of the most typical childhood cancers. Now, researchers from VHIR have identified new microRNAs that reduce the progression of this type of cancer. The participation of NANOMOL group and NANBIOSIS unit 6 Biomaterial Processing and Nanostructuring Unit, as experts in nanoparticles and nanovesciles for nanomedicine, is on the synthesis of the adequate nanocapsules to protect, stabilize and direct this microRNAs molecules to t[...]

31 Mar

Laura Lechuga, Scientific Director of NANBIOSIS Unit 4 is interviewed by CIBER Bulletin

Laura M. Lechuga, group leader of the CIBER-BBN at the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and Sccientific Director of NANBIOSIS Unit 4 Biodeposotion Unit explains her research in an interview to CIBER Bulletin[...]

21 Mar

Meshes in a mess: Mesenchymal stem cell-based therapies for soft tissue reinforcement

Unit 14 of Nanbiosis of Cell Therapy, led by Javier García Casado, has published a review on advances in the development of surgical meshes combined with stem cells. The work of the Nanbiosis team has been published in the prestigious journal “Acta Biomaterialia”[...]

15 Mar

Nanobiosensors for the monitoring of brain lesions

On March 11, the first meeting of the European project ABISens “Monitoring of Acquired Brain Injury and recovery biomarkers by the combined label-free nanoSensing of multiple circulating molecules” was held at the facilities of the Catalan Institute of Nanoscience and Nanotechnology ICN2. This new initiative aims to offer a new platform for photonic nanobiosensors that allows the identification and quantification of multiple brain biomarkers in blood with high sensitivity and in a short time. The new platform will use nanophotonic circuits in combination with the chemistry of oligonucleotides. Two units of NANBIOSIS participate in the project Unit 4 Biodeposition and[...]

13 Mar

“Matrioskas” of nanoparticles, a new therapeutic approach against tuberculosis

Researchers of NANBIOSIS U9 Synthesis of Nanoparticles Unit Manuel Arruebo and Víctor Sebastián have participated in a research published in the journal Nanomedicine Tuberculosis is an infectious disease that poses a serious public health problem and, according to WHO data, 10.4 million people became ill with tuberculosis and 1.7 million died in 2016. Therefore, advance in the development of new tools for diagnosis and treatment is essential and the use of nanoparticles could open a new horizon to deal with the infections caused by Mycobacterium tuberculosis. In this line, researchers from the CIBER at the University of Zaragoza, and at[...]

24 Feb

Micro & nano(bio)technology for Diagnosis: Changes and Challenges

Pilar Marco, Scientific Director of NANBIOSIS U2 Custom Antibody Service (CAbS) participated as Keynote speakers at the Second European Biosensor Symposium (EBS2019) taking about “Micro & nano(bio)technology for Diagnosis: Changes and Challenges” at the 2nd European Biosensor Symposium 2019 that took place in Florence (Italy) Last February 18-21. The EBS brougth toguether young scientists, experienced researchersand companies to push forward new approaches on biosensor and and their applications, Pilar Marco spoke abaut the changes ocurred on the field of Diagnosis since the days of “house calls”, relying primarily on physical examination, to nowadays in which a wide portfolio of biochemica[...]

20 Feb

The European Union highlights the relevance of the JUMISC’s Cutting-Edge Infraestructures and Technology, recognized as ICTS.

Jesús Usón Minimally Invasive Surgery Center (JUMISC), from Cáceres, partnert of NANBIOSIS, has recently made headlines on the website of the European Commission as an innovative center for Biomedical and Health Research. In the interview to his Director, Francisco Miguel Sanchez Margallo, he explained how European Funds allowed Infraestructures and Vanguard Technology for biomedical research at the CCMIJU, which have already been recognized, as part of NANBIOSIS, with CIBER-BBN and BIONAND, as “Singular Scientific and Technical Infrastructure” (ICTS). Complete news at European Commision’s Website: https://ec.europa.eu/spain/news/investeu_caceres_es https://ec.europa.eu/spain/news/investeu_caceres_es[...]

16 Feb

GLP Analytical Validation Study in Different Animal Species

Beatriz Moreno Lobato and Francisco Miguel Sánchez Margallo, Scientific Director and Coordinator of NANBIOSIS unit 19 Clinical tests lab at CCMIJU, have reclently published an study in the journal Thrombosis & Haemostasis: Research, with the aim to contribute with methodological results data to help the researcher to establish the validation of the analytical methods used within the research. Good Laboratory Practice (GLP) is a quality system of management controls to ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity of pre-clinical safety tests. In the study, different hematological parameters (WBC, RBC, HB, HCT, MCV, MCH, MCHC, and PLT) were validated in pig,[...]

12 Feb

PILAR MARCO, Scientific Director of NANBIOSIS U2, interviewed by CIBER-BBN ISCIII Bulletin

Pilar Marco, Scientific Director of NANBIOSIS U2 Custom Antibody Service (CAbS) has been highlighted in the January Bulletin of CIBER-BBN ISCIII In the interview, among other topics Prof. Pilar Marco talks about diagnostic devices based on nanobiosensors and the extraordinary impact that these technologies could have on health in the coming decades. Her research group Nb4D (Nanobiotechnology for Diagnosis) has an important collection of specific antibodies for different biomarkers and the CIBER-BNN/IQAC-CSIS platform CAbS (Custom Antibody Service) that constitutes the unit 2 of NANBIOSIS, they offer the possibility of producing specific and immunoreactive antibodies with the necessary expertise to generat[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

10 Feb

Label-free bacteria quantification in blood plasma by a bioprinted microarray based interferometric point-of-care device

Prof Laura Lechuga, Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit is coauthor of an article publish by ACS Sonsors that shows a portable and autonomous device based on optical interferometry that, when used with specialized nanoplasmonic, can detect directly bacterial cells of the patient’s blood plasma. The work demonstrates the potential of a microarray based POC device for bacteria quantification. The contribution of NANBIOSIS, in particular Unit 4, has been fundamental by providing the  molecular printers necessary for the generation of the biofunctionalized specific microarrayed chips used for the bacteria detection. P. Dey, N. Fabri-Faja, O. Calvo-Lozano, R.[...]

09 Feb


The 5th project face to face meeting has taken place in Cáceres (Spain). The first version of the PICCOLO prototype was set up at CCMIJU, facilities at the end of 2018, and it has been a great chance to show it to the PICCOLO consortium members. During these two days of the meeting, the technical partners presented both the individual components of the prototype (MPT and OCT) and the integration of the same in the probe of the multi-photonic system. The attendants have been able to check in-situ the performance of the prototype in the operating rooms of CCMIJU. Based[...]

06 Feb

STRYKER & NANBIOSIS start a promising line of biomedical research collaboration

On January 23-24th a two-day meeting between NANBIOSIS and Stryker Trauma GmbH, took place at the Carlos III Health Institute, in Madrid, to explore synergies and potential joint initiatives.   Nils Reimers and Robin Buescher from Stryker, presented some of their research and upcoming projects in the field of trauma medical devices, and representatives from NANBIOSIS’ units -Marisa González from U16 Surface Characterization and Calorimetry Unit, Teresa Galán from U7, Nanotechnology Unit, Gemma Pascual from U17 Confocal Microscopy Service, from CIBER-BBN, Marisa García from U28 (Bionand) and José Francisco Guillén and Francisco Sanchez Margallo from the units of the Jesús[...]

05 Feb

Laura Lechuga, Scientific Director of Unit 4 of NANBIOSIS Coordinates a EuroNanoMed project

ABISENS Monitoing of Acquired Brain Injury and recovery biomarkers by the combined label-free nanosensing of multiple circulating molecules is one of the project awarded in the EuroNanoMed III joint call, will be coordinated by Laura Lechuga through the CIBER-BBN Abisens will employ the Unit 4 of Nanbiosis, Biodeposition and Biodetection Unit or the multiplexed biofunctionalization of the biosensor chips and their methodology optimisation The evaluation of patients after brain injuries, which produces severe impairments, remains a major unmet clinical need. Nowadays the diagnosis, prognosis and the efficacy of rehabilitation treatments are mainly assessed by clinical examinations, neuroimaging and electrophysiological tests during a long hospitalization[...]

04 Feb

NANBIOSIS Against Cancer

The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths. Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%. The only way to understand cancer and,[...]

03 Feb

Rosa Villa explains how New graphene implants can help to better understand the brain

A graphene implant that detects brain activity at extremely low frequencies could improve the technology of the electrodes to analyze the state of our brain, has been developed by researchers from several research institutes of the CSIC in Catalonia and the CIBER-BBN. Last First of February , Rosa Villa, Scientific Director of NANBIOSIS U8 Micro – Nano Technology Unit was interviewed in Ágora, a program of Scientific Dissemination of Radio Aragón. Dr. Villa, researcher of the Biomedical Applications Group of the Institute of Microelectronics of Barcelona and CIBER in Bioengineering, Biomaterials and Nanomedicine, explains the relevance of the research carried[...]

02 Feb

Cancer metabolism in a snapshot: MRS(I)

Margarida Julià‐Sapé, Ana Paula Candiota and Carles Arús, Scientific Director and Scientific Coordinators of Nanbiosis U25 NMR: Biomedical Applications I, are the authors of a new article in the journal NMR in Biomedicine: “Cancer metabolism in a snapshot: MRS(I)” The article contains a revision of the contribution of MRS(I) to the in vivo evaluation of cancer‐metabolism‐derived metrics, mostly since 2016. Strategies include the following: (1) quantification of single oncometabolite content such as 2HG; (2) selected metabolite ratios such as total Cho to NAA in gliomas, ratios related to Cho, Cr, citrate and polyamines in prostate cancer or Lac/Pyr in hyperpolarized[...]

01 Feb

Quatsomes. A new family of nanocarriers for drug delivery

The XXXVII edition of the Biennial Meeting of the Spanish Royal Society of Chemistry (RSEQ) will be held from the 26th to the 30th of May in Donostia-San Sebastian.  Prof. Jaume Veciana, Scientific Director of NANBIOSIS and unit 06  of NANBIOSIS -ICTS  Biomaterial Processing and Nanostructuring Unit, will present on May 28th 2019 a lecture entitled “Quatsomes. A new family of nanocarriers for drug delivery” at the Simposium “From Chemistry to Nanomedicine” (http://bienal2019.com/simposios.php). In this lecture the advantages and disavatages of such a kind of nanocarriers will be presentaed as well as some of their applications as nanomedicines.” Deadline for sending abstracts: January 30 (http://bienal2019.com/en/communications.php)&nbs[...]

29 Nov

New device could monitor treatments with anticoagulant to achive personalized therapies

Researchers from NANBIOSIS units 2 and 4 have designed a biosensor device based on gold nanostructures that precisely detects the presence of the anticoagulant drug from a small blood sample. Treatments with anticoagulants such as Sintrom® (acenocoumarol) face the difficulty of adjusting the drug doses. This device will allow patients to self-regulate the dose.   Researchers of NANBIOSIS unit 4  Biodeposition and Biodetection Unit of the Consejo Superior de Investigaciones Científicas (CSIC), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and CIBER Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) have developed a biosensor device which allows the monitoring of anticoagulants such as Sintrom® (acenocoumarol) to[...]

25 Nov

Bionand, recently incorporated to NANBIOSIS ICTS, among the three national biotechnology reference centers.

The Diario Sur of  Andalucía, publishes today  an article dedicated to BIONAND and its recent accreditation as ICTS by the Ministry of Science, Innovation and Universities, that resolved on November 6 the incorporation of the Nanoimaging Unit of BIONAND to the ICTS NANBIOSIS. In the article, the Director of BIONAND, Jose Becerra Ratia, Professor of Cell Biology of the University of Malaga, explains the opportunities and commitments that imply for the Andalusian Center for Nanomedicine and Biotechnology (BIONAND) its incorporation to NANBIOSIS.[...]

24 Nov

Antimicrobial peptides are a promising kind of molecules to fight multi-drug resistant bacteria

The project titled “Breaking the boundaries of resistance to antimicrobials; searching for new antimicrobials against multiresistant bacteria: work on polycytonic peptides and lipid nanoparticles (BARNAPA)” in which participates Fernando Albericio, Scientific Director of NANBIOSIS unit 3 Synthesis of Peptides Unit, has been selected by La Marató TV3 and finnaced with 383.276,25 €. According to Fernando Albericio, the project arises from the need of effective and safer antibiotics to fight resistant and multi-drug resistant bacteria. In this sens, the proyect developed in collaboration with Miquel Vinyas of the UB and with the Stefania Stefani group of the Universita de Catania  looks at antimicrobia[...]

23 Nov

Two units of NANBIOSIS in the project selected by La Marató TV3 to fight against bacterial infections

La Marató TV3 in its call for biomedical projects in infectious diseases has selected the project “Uses of molecular analysis of Quorum Sensing with the diagnosis of bacterial infections” of the Nb4D group, led by Mª Pilar Marco, Scientific Director of unit 2 of NANBIOSIS and in which Miriam Royo also participates Scientific Coordinator of unit 3 of NANBIOSIS, both in the IQAC-CSIC of Barcelona The project of the Nanobiotechnology for Diagnosis (Nb4D) group of the CSIC and the CIBER-BBN has been selected among more than 200 candidates as a project of scientific excellence to be funded in the ca[...]

22 Nov

Lysosomal Rare Disorders: Focus on Fabry Disease

Last November 19, Vall d’Hebron held a seminar  on Lysosomal Rare Disorders: Focus on Fabry Disease as  part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European Commission, the Center for Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the CIBBIM-Nanomedicine at Vall d Hebron Research Institute (VHIR) through the Smart-4-Fabry projec In the  second plenary session, moderated by Nora Ventosa and Simó Schwartz, Scientific Directors of NANBIOSIS units 6 and 20 and devoted to New therapeutic strategies for lysosomal disorders, the speakers presented their findings regarding biomarkers, genetic variants and treatment protocols.[...]

21 Nov

BIONAND incorporated to the Spanish ICTS Map as a new node of NANBIOSIS

The Scientific, Technological and Innovation Policy Council (CPCTI) of the Spanish Ministry of Science, Innovation and Universities has recently approved the updating of the National ICTS Map (Unique Scientific Technological Infrastructures). ICTS are large installations, resources, facilities and services, unique in its kind, that are dedicated to cutting edge and high-quality research and technological development, as well as to promote exchange, transmission and preservation of knowledge, technology transfer and innovation. After the evaluation by the CPCTI of the ICTS activity during the last four years, NANBIOSIS maintains its presence in the new National ICTS Map, but it introduces a novelty[...]

20 Nov

NANBIOSIS with the research appointment “Towards a New Horizon”

NANBIOSIS has attended today the  10th  Research and Innovation Framework under the slogan “Towards a New Horizon“, organized by the CDTI and the European Commission, in collaboration with the Board of Castilla La Mancha has been held on November 20 in the downtown Congress Center of Toledo “El Greco“. The objective of the Conference has been to review the new developments and analyze the participation of Spain in Horizon 2020 in order to draw conclusions that allow Spanish entities to better face the next calls for proposals. The new proposal of the European Commission (EC) for Horizon Europe has also[...]

19 Nov


Members of the NANBIOSIS Coordination Committee have visited the ALBA Synchrotron and its representatives to exchange common research lines, points of view on their complementarity and discuss the collaboration possibilities of the facilities,  both recognized as Unique Scientific Technical Infrastructure  (ICTS) by the Spanish Government. The ALBA Synchrotron consists of a complex of electron accelerators in which the electrons are forced to rotate at a speed of 1 million turns per second. When they are bent, synchrotron light is emitted, allowing to visualize the atomic structure and molecular analysis of materials and study their properties obtaining information that cannot b[...]

16 Nov

NANBIOSIS renews its accreditation as Unique Scientific Technological Infrastructure (ICTS)

NANBIOSIS is one of the 29 ICTS (Unique Scientific Technological Infrastructures) recognized by the Scientific, Technological and Innovation Policy Council (CPCTI) of the Ministry of Science, Innovation and Universities. On November 6, the Council approved the updating of the ICTS Map in which the accreditation of Nanbiosis is renewed as one of them. The new Map is integrated by 29 ICTS, which bring together a total of 62 infrastructures, all of them operative. In the new update the number of ICTS is maintained, but the number of infrastructures is increased by the incorporation of new nodes to existing distributed ICTS.[...]

15 Nov

NANBIOSIS in the Posters presentation in CIBER-BBN ANNUAL CONFERENCE 2018

Last 12 and 13 of November, CIBER-BBN  has celebrated its 12th Annual Conference in Hotel Felipe IV in Valladolid. In poster session participated  NANBIOSIS  itself and some of its units. NANBIOSIS, Infrastructure for the Production & Characterization of Biomaterials, Nanomaterials and medical devices up to preclinical validation. Nanbiosis management team. Divalent cation effects on assembly of histidine-rich protein nanoparticles. López-Laguna, U. Unzueta, O. Conchillo-Solé, A. Sánchez-Chardi, M. Pesarrodona, O. Cano-Garrido, E. Voltà, L. Sánchez-García, N. Serna, P. Saccardo, R. Mangues, A. Villaverde, E. Vázquez (NBT-UAB) (U1 -U18) Antimicrobial peptides (AMPs) anchored on the surface of contact lenses to prevent corneal infections. Emiliano Salvagni, Clara García,[...]

13 Nov

Marisa González, Scientific Director of Unit 16 of NANBIOSIS, candidate to the Rectorate of the University of Extremadura

Marisa González, Scientific Director of NANBIOSIS Unit 16 Surface Characterization and Calorimetry Unit, runs for elections to the Rectorate of the University of Extremadura, to be held on November 27. Marisa González, Professor of Applied Physics in the Faculty of Sciences and the Group Leader of  Microbial Adhesion research group of CIBER-BBN at University of Extremadura, she works with implants and materials on contact with body fluids and tissues, such as blood or bones, and the importance of knowing how these surfaces interact with proteins and molecules in the blood, and how they would do it in case of that bacteria could arrive that[...]

12 Nov

CIBER-BBN Annual Conferences in Valladolid 12-13 November

CIBER-BBN Annual Conferences are taking place now in Hotel Felipe IV in Valladolid, 150 scientists in the field of nanotechnology, biomaterials and bioengineeering gather to share their progress during this year, present their projects and seek synergies for collaboration. The NANBIOSIS Session will take place this afternoon at 16:30, and at 18:30 will take place NANBIOSIS Scientificic Advisory Board meeting                                       &nbs[...]

08 Nov

Update and improvement of unit 20 of NANBIOSIS

NANBIOSIS, U20. In Vivo Experimental Platform, led by Dr. Simó Schwartz and Dr. Ibane Ibasolo, has been recently updated and improved as a result of its participation in the project FICTS1420-20, selected by the MICINN for co-financing by the FEDER Program in ICTS 2014-2020.  These update and improvement include: DLS meassurement system, a fluorimeter and a waterbath for specific activity assays. The fine characterization of the size and size distribution of nanoparticles is essential for the right understanding of their in vivo behavior. The incorporation of this service to the U20 allows the determination of the drug/fluorophore loading/activity of the drug delivery systemistered in vivo, a good quality[...]

07 Nov

Nanomedicine: how to get drugs to the place where they have to act.

At the beginning of June, the Jury of the Rei Jaume I 2018 Awards, formed by Nobel Prize winners, businessmen and scientists, met in Valencia to choose the winners. Today has taken place the ceremony of delivery of the 30th edition of the awards presided over by King Felipe VI. Among the six winners, in the category of New Technologies was Ramón Martínez Mañez, Scientific Director of the CIBER-BBN and Unit 26 of NANBIOSIS. Coinciding with its thirtieth anniversary, the Rei Jaume Foundation has produced a series of videos of interviews with the winners. In this video, Ramón Martínez Mañez,[...]

04 Nov

Preclinical Study for Brain Tumor with Novel Contrast Agents for MRI

Ana Paula Candiota and Carles Arús, Scientific Cordinator and Scientific Director of  U25 of NANBIOSIS, NMR: Biomedical Applications I  have participated in the research published by ACS Applied Materials & Interfaces Journal  that include a preclinical study carried for brain Tumor. Extensive attention has been paid on designing and developing functional imaging contrast agents for providing accurate noninvasive evaluation of pathology in vivo. However, alse-positives or ambiguous imaging and the lack of a robust strategy for simultaneous dual-mode imaging remain to be fully addressed. One effective strategy for improving it is to  design magnetic resonance imaging (MRI) contrast agents (CAs) wit[...]

03 Nov

NANBIOSIS resarchers in CCMIJU identify biomarkers for bridging the gap between preclinical studies in large animal models and clinical trials

Researchers of NANBIOSIS Units at CCMIJU have publish a very relevant article about the studies on  hematological, biochemical and immunological parameters, as well as magnetic resonance derived cardiac function measurements obtained from a swine myocardial infarction model that allows to predict the severity of myocardial infarction in a clinically relevant animal model providing a  simple, affordable and reliable way that could prove useful in the follow up of myocardial infarction and in the evaluation of new therapeutic strategies in this animal model. Biochemical and hematological determinations were performed by the ICTS Nanbiosis (Unit 19. Clinical test lab at CCMIJU). Flow cytometry analyses were performed by the ICTS Nanbiosis[...]

01 Nov

The revolution of nanomedicine by Ramón Martínez Mañez

Ramón Martínez Mañez, Scientific Director of Unit 26 of NANBIOSIS NMR: Biomedical Applications II, will be next Monday, November 5 at 7 pm at the Headquarters of Alicante City (San Fernando, 40), where he will impart the conference “The scientific revolution of Nanomedicine,” The professor of Inorganic Chemistry of the UA and director of the Nanotechnology laboratory, Javier García Martínez, will present the meeting, organized by the Fundación Premios Rey Jaume I and the UA, with the collaboration of the Valencian Agency and Innovation and the Classroom of Science and the Technology of the University of Alicante. Ramón Martínez-Máñez, director of[...]

31 Oct

FUNCATH: Prevention of infectious diseases with functionalized catheters awarded by La Marató de TV3

FUNCATH project,  coordinated by scientists of NANOMOL  group, led by Dr. Imma Ratera, has been awarded by Fundació La Marató de TV3 . NANOMOL is the research group that coordinates NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit, from ICMAB-CSIC and CIBER-BBN. Fundació La Marató de TV3 2017 call was dedicated to infectious diseases and awarded 36 projects among the 186 evaluated according to their excellence, methodology and relevance. FUNCATH is the project for Prevention of infections related to vascular catheters by functionalizing catheters impregnated with thermically activatable hydrogels with broad spectrum antimicrobial agents, whose ultimate goal is the development of vascular catheters coated with multibiofunctiona[...]

24 Oct

NANBIOSIS at the Assembly of Materplat

Next November 14 the General Assembly of Materplat 2018 will take place  in the facilities of the Institute of Ceramics and Glass of the CSIC (ICV-CSIC), on the campus of the Autonomous University of Madrid (Cantoblanco, Madrid). This year, the theme of the Assembly will be focused on how innovation in materials that can be useful in different fields related to smart cities. In this sense, different speakers will show developments in materials very important for sectors such as health, among others. NANBIOSIS will be present through José Becerra, Professor of Cell Biology at the University of Málaga, Scientific Director[...]

15 Oct

NANBIOSIS participation in CPhI Worldwide

NANBIOSIS has participated in the most important event of the pharmaceutical industry, CPhI Worldwide, the largest fair held in Spain. More than 45,000 professionals from more than 150 countries of the main companies in the sector and more than 2,500 companies meet at IFEMA (Madrid) from 9 to 11 October. One of the novelties to be taken into account in this edition of the CPhI Worldwide will be the presentation of biological products by the bioLIVE platform, highlighting the recent growth of biological medicines. BioLIVE, adjacent to CPhI Worldwide in 2018, is the exhibition and conference for large molecule biopharma needs.[...]

11 Oct

Nanoparticles characterization techniques of NANBIOSIS unit 6

The Unit 6 of NANBIOSIS, Biomaterial Processing and Nanostructuring Unit, has organized during the days 8 to 11 of October in the ICMAB-CSIC a course of characterization of Nanoparticles showing some of their techniques to the CSIC researchers. Amable Bernabé, the technician of unit 6 of NANBIOSIS has shown the theory and practice of some methods to characterize nanoparticles and how to handle the necessary equipment. Specifically, these techniques were: Dynamic Light Scattering (DLS) with Zetasizer Nano ZS (Malvern Instruments) Size distribution Z Potential Nanoparticle Tracking Analysis (NTA) with Nanosight NS300 (Malvern Instruments) Size distribution Particle concentration Fluorescence Light Scattering (LS) with Mastersizer 2000 (Malvern[...]

09 Oct

Researchers of NANBIOSIS U9 awarded for a work on scaffolds for dental regeneration

Researchers Manuel Arruebo and Víctor Sebastián, from the CIBER-BBN group led by Jesús Santamaría (NFP) at the University of Zaragoza, that coordinates NANBIOSIS Unit 9 Synthesis of Nanoparticles, have received the second prize of the Resomer Awards granted by the company Evonik, a international recognition to competitiviness. Their work “Promoting bioengineered tooth innervation using nanostructured and hybrid scaffolds”, has been published in the journal Acta Biomaterialia 50 (2017) 493-501. In this work, the researchers of the CIBER-BBN manufactured biodegradable materials such as scaffolds to promote dental regeneration. These scaffolds contained an immunosuppressive drug that, in addition to avoiding rejection after implantation,[...]

05 Oct

Ramón Martínez Máñez Master class on Nanomedicine at the Act of the Academic Opening year 2018-2019  of Spanish university

On September 25, the Polytechnic University of Valencia hosted the Solemn Act of the new Academic Opening year 2018-2019  of Spanish universities, coinciding with the commemoration of its 50th anniversary. This institutional act was chaired by S.M. King Felipe VI, the Minister of Science, Innovation and Universities, Pedro Duque, and the President of the Generalitat Valenciana, Ximo Puig, among many other authorities. Ramón Martínez Máñez, has been in charge of teaching the master class of the new academic year. Ramón Martínez is professor of the Department of Chemistry of the UPV and director of the Interuniversity Research Institute of Molecular[...]

27 Sep

NANBIOSIS participation in BioSpain 2018

NANBIOSIS participates in BioSpain 2018, which is taking place in this ninth edition, in Seville, on September 25-27. BioSpain is one of the main fairs of the European biotechnology sector. It is an event, organized by the Spanish Association of Biocompanies (ASEBIO) in collaboration with  Andalusian government which aims to exchange knowledge, ideas and experiences among all actors in the biotechnology sector. In this edition BioSpain has gathered more than 1,500 attendees, 600 companies and 200 stands. BioSpain is structured in a trade fair, a partnering system that facilitates these meetings, a conference program and an investor’s forum that brings together the most[...]

26 Sep

Nanoparticles in 3D printed bone prostheses that favor regeneration

The research group of Biomaterials for regenerative therapies of CIBER-BBN and IBEC, coordinator of Unit 5 of NANBIOSIS, Rapid Prototyping Unit, led by Elisabeth Engel, expert on nanoparticles and biomaterials, together with the company Avinent, expert in 3D printing, will develop new personalized solutions to improve treatments for bone diseases or injury. So far, they have tested some bioactive nanoparticles based on calcium on the membrane of a chicken embryo and found that blood vessels formed in it and that the cartilage ossified forming a mature bone. The tests were carried out in mice and the result was also positive. The creators[...]

25 Sep

Nanbiosis Contribution to biofilm development

NANBIOSIS Unit 17 Confocal Microscopy Service, has participated in the research results published by Science of the Total Environment  in an article titled “Recycled desalination membranes as support material for biofilm development: A new approach for microcystin removal during water treatment”. The biofilm visualization has been performed by ICTS “NANBIOSIS”  For further information: doi.org/10.1016/j.scitotenv.2018.07.435 &nbs[...]

24 Sep

CIBER-BBN Annual Conference 2018

CIBER-BBN will celebrate its 12th Annual Conference on November 12 and 13 in Vlladolid. In these conference there will be a session dedicated to NANBIOSIS. Likewise, the annual meeting of the Scientific Technical Advisory Committee of NANBIOSIS will take place. As in previous occasions, the meeting will serve to know the activity of NANBIOSIS, the Singular Technical Scientific Infrastructure (ICTS) of the CIBER-BBN and the Minimally Invasive Surgery Center Jesus Usón for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation. The new Cutting-edge Biomedical Solutions of NANBIOSIS wiil be presented.[...]

17 Sep

Prof. Jaume Veciana, Scientific Director of NANBIOSIS: Olivier Kahn Plenary Lecture speaker at the ICMM 2018

Prof. Jaume Veciana, Scientific Director of NANBIOSIS has been honored with the Olivier Kahn Plenary Lecture given at the 16th International Conference on Molecule-Based Magnets (ICMM 2018), held on September 1-5, 2018, in Rio de Janeiro, Brazil. For further information: click her[...]

14 Sep

Label-free DNA-methylation detection by direct ds-DNA fragment screening using poly-purine hairpins

Prof Laura Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit, has led the research whose results have been published by Biosensors and Bioelectronics  with the title  “Label-free DNA-methylation detection by direct ds-DNA fragment screening using poly-purine hairpins” Cancer diagnosis continuously evolves due to the better understanding of tumorigenic processes. DNA-methylation is consolidated as an effective biomarker for cancer prognosis and diagnostic even in tumors of unknown origin. The reversibility of this epigenetic mechanism also places it as a high-profile tool for the development of more sophisticated and personalized therapies. Current methodologies, such as bisulfite conversion or PCR amplification, rely on complex[...]

07 Sep


Dr. Francisco Miguel Sánchez Margallo,  Assistant Director of NANBIOSIS and Scientific Director of JUMISC, has attended the multidisciplinary Congress organized by the Society of Laparoendoscopic Surgeons (SLS), held in New York from August 29 to September 1, where he has presented scientific communications with very innovative results in the specialty of urology. At the annual meeting of this Scientific Society, international specialists related to minimally invasive surgery meet, with the aim of increasing knowledge of laparoscopic, endoscopic and minimally invasive surgical techniques, including robotic surgery. The papers presented by Dr. Francisco M. Sánchez Margallo, have received the Harrith M. Hasson[...]

06 Sep

A new pathway for the prevention of metastasis in colorectal cancer in humans is open: a nanomedicine that selectively eliminates metastatic stem cells

Researchers of NANBIOSIS U18  Nanotoxicology Unit and U1. Protein Production Platform (PPP) at the Biomedical Research Institute of Sant Pau (IIB Sant Pau), of the Hospital of Santa Creu i Sant Pau, of the Universitat Autònoma de Barcelona (UAB), the Superior Council of Scientific Research (CSIC) and the Center for Biomedical Research in Network (CIBER) have published an article in one of the most prestigious international scientific journals in the field of Molecular Medicine, EMBO Molecular Medicine. This article demonstrates the efficacy of the  nanopharmaceutical  that selectively removes metastatic stem cells in animal models of colon cancer. The new drug works like a[...]

05 Sep


The VPH Conference 2018 is taking place in Zaragoza 5-7 September offering an exciting program of state-of-the art science & engineering in computational (bio)medicine, ranging from foundational research on multiscale modelling of human (patho) physiology, via underpinning research on data science and infrastructures for the virtual physiological human, to clinical applications with participation of NANBIOSIS U27. High Performance Computing Esther Pueyo  is charing the Session 3A: Cardiovascular modeling: from simulation to clinical outcome, Some of the outcomes are presented by Jesús Fernández-Bes: A Bayesian Filtering methodology to identify key drivers of ventricular repolarization variability (Jesus Fernandez-Bes, David Adolfo Sampedro-Puente and Esther Pueyo)  Virtual Physiologica[...]

04 Sep

Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma

As a result of the collaboration carried aout by two units of NANBIOSIS, U4. Biodeposition and Biodetection Unit and U2. Custom Antibody Service (CAbS), it has been developed a compact and simple nanoplasmonic sensing device based on gold nanodisks for the rapid monitoring of acenocoumarol, using highly specific polyclonal antibodies produced against the drug Acenocoumarol (Sintrom®) which implies: A label-free nanoplasmonic device for the rapid monitoring of acenocoumarol in plasmaD. Direct quantification in real time requiring low sample volume is achieved. Non-specific interferences from plasma are minimized using the developed methodology. Excellent accuracy has been observed measuring blind plasma samples. Potential to be implemented as a POC devic[...]

29 Aug


On November 2th-30th, Centro de Cirugía de Mínima Invasión Jesús Usón, partner of NANBIOSIS, organizes a theorical and practical course:  “Course for the performance of functions a, b and c in rodents, lagomorfos, carnivores, pigs and small ruminants”. Some researchers of NANBIOSIS Units at JUMISC, will transmit their knowhow and experience to the attendees. The course objetives are to provide adequate training to researchers in the science and welfare of the laboratory animal, as well as the use of bloodless methods of euthanasia that will be carried out with experimental animals in accordance with current legislation and existing recommendations. This course, onc[...]

27 Aug

Recombinant proteins production: optimization strategies.

On October 24th-26th, Aula Científica, in collaboration with IBB, organizes a theorical and practical course on “Recombinant proteins production: optimization strategies“. Some researchers of NANBIOSIS Unit1 Protein Production Platform (PPP), will transmit their knowhow and experience to the attendees, as José Luis Corchero, Rosa Mendoza Moreno and Neus Ferrer Miralles, Scientific Director of the Protein production planform of ICTS NANBIOSIS. The course is aimed at researchers and laboratory technicians from universities, hospitals, companies and research centers who are interested in the expression, production and purification of recombinant proteins with de objectives of analyze and design strategies for the improvement in the expression,[...]

25 Aug

Conversion of Biomolecules into pharmaceuticas Leads using nanovesicles

Nathaly Segovia, Scientific coordinator of NANBIOSIS U 6, Biomaterial Processing and naostructuring unit, explains in this video what the objective of her unit , the services they offer and their technologies  in the field of drug delivery.[...]

24 Aug

Peptides, targeting units and drug conjugates

Miriam Royo, Scientific Coordinator of Unit 3 of NANBIOSIS explains in this video the expertise of the unit in the preparation of difficult peptides (Cyclid and polycyclic peptides, stapled peptides and dificult peptides, depsipetides, natural products and libraries, peptidomimetic libraries, peptides as antigens or adjuvants, tarjeted drug conjugates, etc… as well as therapeutic agen-PEG-targeting unit conjugates[...]

23 Aug

Advanced methods of continuous production of Nanomaterials

Victor Sebastian, researcher of  NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit, explains the production technologies in continuous (Microfluidic systems liquid phase or pyrolysis activated by laser, gas phase in which the nanoparticles are produced)[...]

22 Aug

Micro and nanotechnologies for the release of biotechnological products

José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug formulation, talks in this video about Micro and polymeric nanoparticles, lipid nanoparticles, non-viral vectors for gene therapy and scaffolds for cell therapy and regenerative medicine and bio 3D printing &nbs[...]

20 Aug

Nanoparticle uptake and in vivo estimates of therapeutic efect and toxicity

Ramón Mangues, Scientific Dierctor of unit 18 of NANBIOSIS, Unit of nanotoxicology, explains in this video some of the animal models used in the unit for preclinical validation of nanoparticles, especially of application in cancer[...]

17 Aug

Biodistribution, safety and efficacy studies of pharmacological release nanotechnological systems

Ibane Abásolo, Scientific Coordinator of NANBIOSIS U20, explains in this video the studies of biodistribution, safety and efficacy of nanotechnological systems of pharmacological liberation that are developed in this unit and , overall, their expertise and differentiation in the sector in the evaluation of nanosystems (with certification ISO 901-2015)[...]

16 Aug

Use of Nanomedicine in preclinical studies and animal models

In this video, Beatriz Moreno Lobato, Head of Unit 19 of NANBIOSIS, Clinical Tests Lab and head of the Animal Modeling Service and Clinical Analysis Laboratory of CCMIJU, gives a talk about the use of Nanomedicine in preclinical studies and animal models. Models of type I and II diabetes, cutaneous ulcer models, animal models in ophthalmology, urology models, cartilage defect models or bone defects models and cardiovascular models such as mycardial infarction in pig that Beatriz explains in more detail, as well as implantation of surgical material in combination with adult stem cells[...]

14 Aug

Testing medical devices and drugs GLP Compliance

En este vídeo Jose Francisco Guillen Caro, Responsable de garantía de calidad del CCMIJU presents the Jesús Usón Minimum Invasion Surgery Center in Cáceres and, especially, the UMISC units that integrate NANBIOSIS, as well as the services and tests they perform, which are certified as GLP[...]

13 Aug

NANBIOSIS develops on demand projects and cutting edge biomedical solutions.

In this video, Jesús Izco Ex. Director of NANBIOSIS, presents NANBIOSIS as one of the 29 ICTS that currently make up the national ICTS map. It consist consists of 27 units grouped into five platforms  which ofer their services under a single contact point and develops on demand projects and cutting edge biomedical solutions in different biomedical applications such as biosensors, live image, contrast agents, therapeutic agents, regenerative medicine, drug delivery, among others.   &nbs[...]

10 Aug

NANBIOSIS Youtube channel: new video-presentations and informative capsules about NANBIOSIS activity

NANBIOSIS makes available its youtube channel with informative videos about the ICTS-NANBIOSIS and the activity of some of its research units and platforms, as well as its Cutting-edge Biomedical Solutions and Nanomedicines Cascade Characterizations NANBIOSIS youtub[...]

09 Aug

Manuel Souto received UAB PhD Extraordinary Award

Jaume Veciana and Imma Ratera (NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit) have supervised Manuel Souto’s PhD thesis entitled “Multifunctional Materials based on TTF-PTM dyads: towards new Molecular Switches, Conductors and Rectifiers”. The School for Doctoral Studies, together with UAB Alumni, organises an event every semester for the award of PhD degrees and PhD special prizes. With 66 PhD programmes, the UAB is one of the leading Catalan universities in the production of theses and generates approximately a third of the doctoral theses that are defended in the Catalan university system each year. The PhD special prizes confer value to theses which have received the qualification of excellenc[...]